Side-by-side comparison of AI visibility scores, market position, and capabilities
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
World's largest medical device company with $32.4B FY2024 revenue; Hugo robotic surgery challenges Intuitive Surgical; MiniMed automated insulin system; Patient Monitoring spin-off 2024; NYSE: MDT.
Medtronic plc is the world's largest medical device company, founded in 1949 by Earl Bakken and Palmer Hermundslie in a Minneapolis, Minnesota garage—where Bakken invented the first wearable external pacemaker—and now incorporated in Ireland with operational headquarters in Dublin, trading on NYSE (MDT). The company generated approximately $32.4 billion in revenues for fiscal year 2024 (ending April 26, 2024) under CEO Geoff Martha, spanning cardiovascular, neuroscience, surgical, and diabetes therapy technologies. Medtronic's 2015 acquisition of Covidien for $49.9 billion—at the time the largest medical device merger in history—added surgical instruments, patient monitoring, and respiratory interventions while enabling Irish incorporation that reduced the company's effective tax rate. In 2024, Medtronic announced the spin-off of its Patient Monitoring & Respiratory Interventions segment as an independent company (NewCo), sharpening focus on higher-margin, high-growth therapy areas.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.